Great article from The Wall Street Transcripts on Q (50% upside within 1 year!)
Questcor Pharmaceuticals Inc (QCOR) has potential to make $5 per share in earnings over the next 12 months, with a 50% gain from its current market price due to numerous positive developments at the company, including steady growth of its one-of-a-kind Acthar drug, continued share buybacks, and increased research and development spending, says Brian Poma, Partner and Portfolio Manager at Neumeier Poma Investment Counsel, LLC. “We like to find companies that have some sort of edge over their competition that is highly defensible. Well, Questcor’s lead drug, H.P. Acthar, fits this bill. Acthar is a biologic drug with orphan status that’s approved to treat 19 different indications. Although Acthar has patent exclusivity on just one of these indications, generic competition has never been able to develop a copied version of this drug. This has to do with the complex makeup of Acthar’s 39 aminoacid peptides with impurities that have never been disclosed. Matching these impurities, which is a task that would be required by the FDA in order for a generic company to get approval, has been basically impossible. Further barriers to generics are a proprietary manufacturing process and required FDA clinical trials, which make us feel comfortable that Acthar won’t have a generic competitor for at least the next seven to 10 years, if ever,” Poma said.
Better than a poke in the eye, but sometimes vanilla is all that's being served. Newbies may find it enthralling but the writer fails to see the explosive potential. The writer must not read our board. Jim
What a chickenshiit forecast!!! It actually represents NEGATIVE GROWTH OFF OF Q2 which when annualized is $5.40 EPS for next 4 Q's ($1.35 X 4 = $5.70)...AND I'M STILL IN WITH $1.65 for Q3 and $1.95 for Q4 = $5.73 for 2013...assuming the 30% 5 year growth ANALYST CONSENSUS FORECAST, 2014 would be $7.45 EPS !!!